Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Metric
Company Name	Generation Bio Co.
Symbol	GBIO
MSH ID	COM:GENERATIONBIO
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	174
Website	generationbio.com
LinkedIn
Founders

Metric
Market Cap	155.01M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital	76M

Metric
Revenue	5.90M
Revenue (LTM)
Revenue (NTM)
Gross Profit	641K
EBITDA	-133.30M
Operating Income	-138.56M
Net Income	-126.61M
EPS	-0.00
Diluted EPS	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.65
Operating Profit Margin	-8.49
EBITDA Margin	-22.58
Net Profit Margin	-12.03
Return on Equity	-0.51
Return on Assets	-0.33
Return on Capital Employed	-0.41

COM:GENERATIONBIO

Generation Bio Co.

Last Close

1.32

22/11 21:00

Market Cap

155.01M

Beta: -

Volume Today

326.95K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.04
P/B Ratio	0.53
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	37.61
EV Multiple	-0.71

Metric
Days Sales Outstanding	79.61
Days Payables Outstanding
Days Inventory Outstanding	235.91
Operating Cycle	492.35
Cash Conversion Cycle	347.32
Asset Turnover	0.05

Metric
Operating Cash Flow	-52.74M
Free Cash Flow	-60.14M
Cash Flow to Debt	-0.54
Operating Cash Flow/Sales	-5.70
Free Cash Flow Yield	-0.44

Metric
Cash & Equivalents	66.45M
Accounts Receivable	-3.56M
Inventory	3.82M
Goodwill
Debt to Capitalization	0.45
Debt to Assets	0.21
Current Ratio	9.07
Quick Ratio	8.01

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	7.98
R&D to Revenue	28.85
SG&A to Revenue	16.71